- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Moderate to severe chronic obstructive pulmonary disease (COPD)
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 1227KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 95KB)
Budesonide + glycopyrronium + formoterol – July 2021
Budesonide + glycopyrronium + formoterol: Pressurised inhalation containing budesonide 160 micrograms with glycopyrronium 7.2 micrograms (as bromide) and formoterol fumarate dihydrate 5 micrograms per dose, 120 doses; Breztri Aerosphere®
Last updated
29 October 2021